Ipca Laboratories News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Ipca Laboratories Ltd. authored by Emkay and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Emkay

Keep track of all breaking news and updates on Ipca Laboratories from all sources in a single place.

Ipca Laboratories Ltd.

12 Jun 2026, 05:26PM

1583.00

-1.90%

Company Update

Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

pdf

Ipca Laboratories Ltd.

09 Jun 2026

1583.00

-1.90%

Company Update

Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Eclsoed copy of newspapers

pdf

Ipca Laboratories Ltd.

02 Jun 2026

1583.00

-1.90%

Sharp price-value disconnect emerging

Buy: Ipca Laboratories Ltd.

Emkay

Ipca’s 4QFY26 EBITDA was ahead of our expectations (broadly in line with the consensus’). The beat was driven by higher overall sales, a marginally higher gross margin, as well as lower staff costs.

Ipca Laboratories Ltd. is trading above all available SMAs

Ipca Laboratories Ltd.

02 Jun 2026

1583.00

-1.90%

Ipca Laboratories (IPCA IN) Q4FY26 Result Update Strong FY27 guidance BUY

Buy: Ipca Laboratories Ltd.

Prabhudas Lilladhar

IPCA reported strong EBITDA of INR 4.9bn (up 19.6% YoY), 7% above our estimates. Company has guided strong revenue growth of 12-13% and 150 bps margin expansion in FY27. Our FY27 and FY28E EPS stand increased by 2-3% which factors in 11% revenue growth in FY27. Domestic formulation and branded generic business, which now contributes 46% of revenues and ~70% of EBITDA, continued to outperform and grow at healthy levels. We believe 1) recovery in API segment 2) higher margins ex Unichem 3) steady growth in domestic formulation are the key growth drivers. At CMP, the stock is trading at 14.5x EV/EBITDA and 23x PE on FY28E adjusted for Unichem stake. We...

Ipca Laboratories Ltd. has an average target of 1793.75 from 4 brokers.

Ipca Laboratories Ltd.

02 Jun 2026

1583.00

-1.90%

Ipca Laboratories

Buy: Ipca Laboratories Ltd.

Target

ICICI Direct

Q4FY26 - Formulations drive numbers- Revenues grew 6.3% YoY to 2388.5 crore, mainly driven by formulations. Domestic formulations grew 12% YoY to 853 crore. Under exports formulations - Branded exports grew ~14% to 190 crore, generic exports also grew 39% YoY to 341 crore whereas Institutional exports de-grew 33% YoY to 74.1 crore. The API business was flat at 344.6 crore. The subsidiaries (including Unichem) performance was also below par with ~6% degrowth to 574 crore. EBITDA grew 13% YoY to 483.9 crore while EBITDA margins improved...

Ipca Laboratories Ltd. has an average target of 1793.75 from 4 brokers.

Ipca Laboratories Ltd.

01 Jun 2026

1583.00

-1.90%

Company Update

Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Copy of Newspaper publications

pdf

Ipca Laboratories Ltd.

01 Jun 2026

1583.00

-1.90%

Company Update

Ipca Laboratories Ltd - 524494 - Revised Link For Q4FY26 Conference Call To Be Held Today

BSE India

Revised Link for Q4FY26 Conference Call to be held today

pdf

Ipca Laboratories Ltd.

01 Jun 2026

1583.00

-1.90%

Domestic/exports formulation drive earnings

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Laboratories (IPCA) delivered in-line revenue in 4QFY28. It delivered 5% beat on EBITDA, driven by higher gross margin. PAT came in line with estimate.